203
Participants
Start Date
June 16, 2015
Primary Completion Date
September 25, 2024
Study Completion Date
September 25, 2024
Tirabrutinib
Capsules or tablets administered orally
Idelalisib
Tablets administered orally twice daily
Entospletinib
Tablets administered orally
Obinutuzumab
Administered intravenously
Institut Universitaire du Cancer-Oncopole I.U.C.T-O, Toulouse
Georgetown University Medical Center, Washington D.C.
Chu Haut Leveque, Pessac
Hopital Saint Eloi, Montpellier
Indiana University Health Goshen Center for Cancer Care, Goshen
CHRU de Lille, Hopital Claude Huriez, Lille
Centre Hospitalier de Lyon Sud, Pierre-Bénite
Oregon Health and Science University, Portland
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff
Leeds Teaching Hosptials NHS Trust, Dept of Haematology, Leeds
University Hospitals of Leicester NHS Trust, Leicester
The Christie NHS Foundation Trust, Manchester
Plymouth Hospitals NHS Trust, Plymouth
University Hospital Southampton NHS Foundation Trust, Southampton
Lead Sponsor
Gilead Sciences
INDUSTRY